secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcadia Biosciences, Inc. (RKDA)
CIK:        0001469443
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0000950170-22-016854
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcadia Q2 revenue surges 175% to $3.9M; net loss improves to $0.17/share
-------------------------------------------------------------------------

- Q2 revenue $3.9M vs $1.4M a year ago, driven by Zola and GoodWheat pasta launch.
- Net loss attributable to common stockholders narrowed 28% to $3.8M ($0.17 per share) from $5.3M.
- First-half 2022 revenue $7.1M, up 217%; net loss $8.3M vs $3.2M, impacted by absence of $10.2M gain on Bioceres stock in 2021.
- Received $2M milestone from Bioceres for HB4 soybean approval in China; part recognized as license revenue.
- Introduced Project Greenfield, a 3-year plan aiming for profitability, focusing on core brands.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1469443/000095017022016854/0000950170-22-016854-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1469443/000095017022016854/rkda-20220811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-016854

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer